The High-Resolution Electron Microscopy Facility (HREMF) was established in 1997 to provide a resource to investigators at the University of Texas M.D. Anderson Cancer Center for High-Resolution imaging of cells, tissues, and nanoscale particles that may be used as drug carriers or imaging agents. The goals of the facility are to provide a shared scanning electron microscopy and transmission electron microscopy resource for members of the M. D. Anderson Cancer Center. The facility occupies 388 sq ft in the R.E. """"""""Bob"""""""" Smith Research Building on the South Campus. A Director, a full-time Research Investigator, and a quarter-time Research Investigator staff the HREMF. The facility houses two electron microscopes: a Joel JEM1010 transmission electron microscope (TEM) and a Joel JEM5900 scanning electron microscope (SEM). Both of the microscopes are equipped with digital cameras that allow users to review their samples on computer monitors. The addition of digital imaging capability has significantly improved the efficiency of the facility and has rendered darkroom processing obsolete. Additional equipment needed to prepare samples for TEM and SEM, such as an ultramicrotome and ultrastainer, are also maintained within the facility. The facility's SEM is equipped with an electron backscatter detector and is the only microscope of its kind available on the M.D. Anderson campus. Similarly, the TEM is the only such microscope that is dedicated solely for research application. The institution acknowledges the value of the HREMF to the M.D. Anderson community by ensuring that the computers are equipped with the most current software and by contributing to the service contracts on the microscopes. The HREMF offers a number of services to our clients including: (a) consultation and assistance in constructing appropriate experimental designs for SEM and TEM, (b) processing of samples for SEM and TEM, (c) assistance with screening of samples, (d) assistance with data interpretation, (e) recommendations for future experiments, and (f) encouraging collaborations. During the previous funding period, HREMF services were used by 82 investigators from 11 of the CCSG programs, which represents a 55% increase over the previous 5-year period. The number of samples processed by the HREMF has increased three-fold since the facility was established in 1997. Peer-reviewed investigators are given priority for services and 74% had peer-reviewed funding and accounted for 52% of utilization. Future plans are focused on adapting new techniques to characterize bioengineered material and nanoparticles.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-34
Application #
7928900
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
34
Fiscal Year
2009
Total Cost
$144,759
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477
Liao, Zhongxing; Lee, J Jack; Komaki, Ritsuko et al. (2018) Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 36:1813-1822
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113

Showing the most recent 10 out of 12418 publications